Active	Status	Sponsor type	Region	Phase	Filter
36 Active 1 Inactive 37 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

36 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Preston, Mark
NCT03216525: Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol	Recruiting	3	136	US	Alvimopan, Entereg, Placebo	Brigham and Women's Hospital, Merck Sharp & Dohme LLC	Bladder Cancer	12/23	06/24
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
BRIDGE, NCT05538663: Intravesical BCG vs GEMDOCE in NMIBC	Recruiting	3	870	US	Gemcitabine, GEMZAR, Docetaxel, Taxotere, Bacillus Calmette Guerin, BCG	ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)	Non-muscle-invasive Bladder Cancer	11/29	10/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve	Recruiting	1/2	222	Canada, US	EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2	enGene, Inc.	Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	06/25	05/27
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer	Completed	N/A	34	NA	Survey Administration	Mayo Clinic, National Cancer Institute (NCI)	Bladder Carcinoma	06/24	06/24
NCT05918263: Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial	Recruiting	N/A	68	US	High-Intensity Interval Training Exercise Program	Dana-Farber Cancer Institute, Prostate Cancer Foundation	Prostate Cancer, Prostatic Neoplasms	03/26	03/27
Kates, Max
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)	Recruiting	3	112	Europe, US	ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)	Fidia Farmaceutici s.p.a.	Bladder Carcinoma in Situ (CIS)	11/25	11/27
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
GEMDOCE, NCT04386746: Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer	Active, not recruiting	2	27	US	Gemcitabine, Gemzar, Docetaxel, Taxotere	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Urothelial Carcinoma Bladder, Bladder Cancer	10/22	11/25
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Recruiting	1	60	Europe, US	UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine	UroGen Pharma Ltd.	Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	12/25	12/25
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer	Completed	N/A	34	NA	Survey Administration	Mayo Clinic, National Cancer Institute (NCI)	Bladder Carcinoma	06/24	06/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer	Active, not recruiting	N/A	572	US		University of Washington, Patient-Centered Outcomes Research Institute	Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer	12/24	03/25
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry	Recruiting	N/A	4400	US	Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system	Photocure, Catalyst Pharmaceutical Research	Bladder Cancer	12/28	12/28
Dickstein, Rian
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve	Recruiting	1/2	222	Canada, US	EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2	enGene, Inc.	Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	06/25	05/27
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients with Non-Muscle Invasive Bladder Cancer	Recruiting	1	24	US	ZH9	Prokarium Ltd	NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer	06/25	07/27
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer	Active, not recruiting	N/A	572	US		University of Washington, Patient-Centered Outcomes Research Institute	Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer	12/24	03/25
Mazzarella, Brian
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC	Recruiting	2	50	US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	High-Risk Non-Muscle-Invasive Bladder Cancer	03/27	12/27
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System	Active, not recruiting	N/A	279	US	Zenflow Spring System, Sham Procedure, Foley Catheter	Zenflow, Inc.	BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)	06/24	06/26
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer	Terminated	N/A	3	US	NanoTherm Ablation	MagForce USA	Prostate Cancer	07/23	07/23
NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)	Active, not recruiting	N/A	225	Europe, Canada, US	ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath	ProVerum Medical	Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms	03/24	12/28
NCT06236802: ProVIDE II Bridging Study	Active, not recruiting	N/A	40	Europe, US	ProVee device, ProVee Expander, ProVee	ProVerum Medical	BPH With Symptomatic Lower Urinary Tract Symptoms	09/24	06/29
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm	Recruiting	N/A	120	Europe, US	UroLift, Rezum	NeoTract, Inc.	Benign Prostatic Hyperplasia	05/25	12/25
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer	Not yet recruiting	N/A	280	Europe, Canada, US, RoW	Aquablation Therapy, Radical Prostatectomy	PROCEPT BioRobotics	Localized Prostate Cancer	07/27	01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Penshorn, Jennifer
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer	Terminated	N/A	3	US	NanoTherm Ablation	MagForce USA	Prostate Cancer	07/23	07/23
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs	Recruiting	N/A	125	US, RoW	Robotic Waterjet Treatment, Aquablation therapy	PROCEPT BioRobotics	Benign Prostatic Hyperplasia, Localized Prostate Cancer	08/25	05/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Wright, Katie
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Active, not recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Wlajnitz, Tina
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
Thai, Siline
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30